HLB Pharmaceutical’s Rights Offering Draws 2,880% Subscription Rate Ahead of FDA Decision, Signaling Surge in Investor Sentiment

HLB Pharmaceutical drew market attention after recording a 2,880% subscription rate in the public offering portion of its rights offering. The result confirms strong confidence among South Korean investors in Korean biotech companies despite continued global macroeconomic uncertainty. The offering’s success comes as the U.S. Food and Drug Administration (FDA) is set to decide on approval of lirafugratinib, a cholangiocarcinoma treatment developed by HLB’s U.S. subsidiary Elevar Therapeutics, on Sept. 25.

Record subscription rate demonstrates investor confidence

HLB Pharmaceutical disclosed the results of its public offering subscription through the Electronic Disclosure System on the 17th. The rights offering will issue a total of 10,762,332 shares, and existing shareholders subscribed for 9,839,398 shares, representing a subscription rate of 91.42%. The public offering for the 922,934 unsubscribed shares remaining after the existing shareholders’ offering attracted a total of 26,581,654 shares. These included 24,196,654 shares from general investors, 1.77 million shares from high-risk, high-return investment trusts, and 615,000 shares from venture company investment trusts.

The resulting public offering subscription rate was 2,880.13%. The cumulative number of subscribed shares, combining the existing shareholders’ and public offerings, was 36,421,052, for an overall subscription rate of 338.41%. Refunds and payment of the subscription price are scheduled for the 18th, and the new shares are scheduled to be listed on Oct. 7.

HLB previously saw its market capitalization decline as FDA approval of rivoceranib, its liver cancer drug, was repeatedly delayed, and suffered another setback when it was removed from the MSCI Korea Index at the end of August 2026. Even as passive fund outflows became unavoidable, the record success of this rights offering shows that strong liquidity among South Korean retail and institutional investors is helping offset the withdrawal of foreign capital.

Global commercialization accelerated through simultaneous FDA and EMA strategies

The key reason foreign investors are focusing on the HLB Group is the global regulatory timeline for lirafugratinib, a cholangiocarcinoma treatment. With the FDA’s Prescription Drug User Fee Act (PDUFA) action date approaching on Sept. 25, 2026, Elevar Therapeutics also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) on Sept. 14, pursuing simultaneous entry into the U.S. and European markets.

In the ReFocus phase 1/2 clinical trial, lirafugratinib recorded an objective response rate (ORR) of 46.5%, a median duration of response of 11.8 months, and a median overall survival of 22.8 months. Its selective inhibition of FGFR2 is also considered a competitive advantage because it substantially reduces the incidence of adverse effects such as hyperphosphatemia (20.7%) and diarrhea (21.6%), which are commonly observed with existing nonselective inhibitors.

“For HLB, whether lirafugratinib receives FDA approval means more than bringing a single drug to the U.S. market,” an industry official in the pharmaceutical and biotech sector said. “It will be the most important test of whether the company can restore market confidence, shaken by repeated delays in approval of its liver cancer drug, through the tangible achievement of FDA approval.”

FDA approval could catalyze a reassessment of K-bio

The FDA’s final decision on Sept. 25 is expected to be a watershed moment that will determine the value of the HLB Group as a whole. If approval is secured, the pipeline risk associated with relying solely on the liver cancer drug will be resolved, and the company will be able to fully activate its U.S. commercialization organization. Foreign investors are watching to see whether HLB can move beyond being an R&D-focused company and become a global commercial pharmaceutical company that directly sells new drugs in the United States and Europe. If approved, the drug could catalyze a strong return of foreign capital to the broader K-bio sector.

The large amount of capital raised by HLB Pharmaceutical through the rights offering is scheduled to be invested in expanding pharmaceutical facilities and strengthening distribution networks after the new shares are listed on Oct. 7. If the group’s drug receives global regulatory approval, it is expected to create synergies supporting stable pharmaceutical production and distribution in South Korea and overseas.